神经降压素受体1作为前列腺癌诊疗一体化潜在生物标志物的评估
该研究通过免疫组化检测97例前列腺癌和100例良性前列腺增生患者组织中神经降压素受体1(NTSR1)的表达,并与PSMA和GRPR比较,同时在PC-3荷瘤动物模型中进行18F-DEG-VS-NT的NTSR1 PET显像。结果显示91.8%前列腺癌组织高或中度表达NTSR1,所有PSMA阴性组织均NTSR1阳性,BPH仅8%强或中度表达;动物模型中该探针肿瘤摄取显著且本底低。结论认为NTSR1是有前景的分子标志物,18F-DEG-VS-NT可用于患者筛选和疗效监测。
要点
- 91.8%前列腺癌组织高或中度表达NTSR1,显著高于BPH的8%。
- 所有PSMA阴性前列腺癌组织均NTSR1阳性,提示互补价值。
- 18F-DEG-VS-NT在PC-3荷瘤模型中肿瘤摄取显著、本底低。
核心结论
- NTSR1是前列腺癌有前景的分子标志物,基于患者组织染色结果。
- NTSR1靶向探针18F-DEG-VS-NT在动物模型中显示高肿瘤/本底对比,可用于筛选NTSR1靶向治疗患者及监测疗效。
研究设计与样本
- 免疫组化检测97例前列腺癌和100例良性前列腺增生(BPH)临床患者组织中NTSR1表达,并比较PSMA和GRPR表达谱。
- PCR检测LnCap和PC-3细胞中NTSR1 mRNA表达。
- 在PC-3荷瘤动物模型中进行18F-DEG-VS-NT的NTSR1 PET显像及生物分布研究。
主要发现
- NTSR1在前列腺癌组织中高或中度表达率为91.8%,PSMA为86.7%,GRPR为65.3%。
- 所有检测的PSMA阴性组织均显示NTSR1阳性表达。
- BPH中仅8%显示NTSR1强或中度表达,显著低于前列腺癌的91.8%。
- PCR显示雄激素依赖性前列腺癌细胞LNCap NTSR1表达阴性,雄激素非依赖性PC-3表达阳性。
- 动物模型中18F-DEG-VS-NT显示显著肿瘤聚集和低本底。
关键数值与推荐
- 前列腺癌组织NTSR1高或中度表达率91.8%(97例),BPH为8%(100例)。
- 前列腺癌组织PSMA表达率86.7%,GRPR表达率65.3%。
- 所有PSMA阴性前列腺癌组织均NTSR1阳性。
临床怎么用
- NTSR1免疫组化可用于前列腺癌患者筛选,尤其PSMA阴性者可能从NTSR1靶向诊疗中获益。
- 18F-DEG-VS-NT PET有望用于NTSR1靶向治疗的患者选择和疗效监测。
局限性
- NTSR1 PET显像仅在PC-3荷瘤动物模型中进行,尚未在患者中验证。
- NTSR1表达评估基于免疫组化染色,未报告与临床结局的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite recent developments in the diagnosis and treatment of prostate cancer, the advanced stages still have poor survival rates. This warrants further exploration of related molecular targets for patient screening, detection of metastatic disease, and treatment/treatment monitoring. Recent studies have indicated that neurotensin receptors (NTSRs) and their ligand neurotensin (NTS) critically affect the progression of prostate cancers. In this study, we evaluated the expression of neurotensin receptor1 (NTSR1) in patient tissues and performed NTSR1 PET imaging in a prostate cancer animal model. METHODS: The NTSR1 expression was evaluated in 97 cases of prostate cancer and 100 cases of benign prostatic hyperplasia (BPH) of clinical patients by immunohistochemistry staining. The expression profile of PSMA and GRPR was also performed for comparison. The mRNA expression of NTSR1 in LnCap and PC-3 cells was measured by PCR. NTSR1 PET, and biodistribution studies were performed in PC-3 xenografts using 18F-DEG-VS-NT. RESULTS: NTSR1 showed high or moderate expression in 91.8% of prostate cancer tissue, compared with PSMA (86.7%) and GRPR (65.3%). All examined PSMA-negative tissues showed positive NTSR1 expression, suggesting the potential complementary role of NTSR1 targeted imaging or therapy. Only 8% of BPH shows strong or moderate expression of NTSR1, which is significantly lower than that in prostate cancer (91.8%). PCR results indicated LNCap (an androgen-dependent prostate cancer cell) showed negative NTSR1 expression while PC-3 demonstrated positive expression (an androgen-independent prostate cancer cell), which correlated well with previously reported western blot results. In a preclinical animal model, NTSR1 targeted PET probe 18F-DEG-VS-NT demonstrated prominent tumor accumulation and low background. CONCLUSION: We have demonstrated that NTSR1 is a promising molecular marker for prostate cancer based on patient tissue staining. The NTSR targeted probe 18F-DEG-VS-NT demonstrated high tumor to background contrast in animal models, which could be valuable in selecting patients for therapies targeting NTSR1 as well as monitoring therapeutic efficacy during treatment accordingly.
引用
- He T, Wang M, Wang H, et al. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use. Eur J Nucl Med Mol Imaging. 2019. PMID: 31264168. doi:10.1007/s00259-019-04355-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。